Contents
1. Executive Summary
2. Global Type 1 Diabetes Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Type 1 Diabetes Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Type 1 Diabetes Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Type 1 Diabetes Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. the Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Insulin Analog: Market Share (2020-2030F)
12.2.1. Rapid-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Long-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Premix Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Drug Class: Market Share (2020-2030F)
12.3.1. Insulin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Insulin Pumps: Market Share (2020-2030F)
12.4.1. Insulin Pen, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Blood Glucose Meters, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.5. By Application: Market Share (2020-2030F)
12.5.1. Children, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Adults, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
14. Abbott Laboratories
14.1. Company Overview
14.2. Company Total Revenue (Financials)
14.3. Market Potential
14.4. Global Presence
14.5. Key Performance Indicators
14.6. SWOT Analysis
14.7. Product Launch
15. Bayer AG
16. Eli Lilly and Company
17. GlaxoSmithKline
18. Johnson & Johnson Ltd.
19. Merck & C0.
20. Pfizer Inc.
21. Takeda Pharmaceutical
22. AstraZeneca PLC.
23. XOMA Corp
24. Other Prominent Players
Consultant Recommendation
The above-give segmentation and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
Select License Type
Our Clients
We have been working with some Fortune 500+ clients
.png){kind=icon}
